Skip to main content
GutCited

Butyrate (Sodium/Calcium Butyrate) के लिए Crohn's Disease

C

Oral butyrate (4 g/day for 8 weeks) improved CDAI scores in open-label study. Controlled evidence still limited.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbutyrate\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

निष्कर्ष

Oral butyrate (4 g/day for 8 weeks) improved CDAI scores in open-label study. Controlled evidence still limited.

Key Study Findings

Randomized Controlled Trial n=140 Double-blind
Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study …
Dose: None बनाम: placebo plus conventional therapy Outcome: clinical disease activity and fecal calprotectin प्रभाव: None p=0.013

जनसंख्या: IBD patients (60 Crohn's disease, 80 ulcerative colitis)

In Vitro
Sodium butyrate alleviates DSS-induced inflammatory bowel disease by inhibiting ferroptosis and modulating ERK/STAT3 signaling and …
Dose: Low-dose and high-dose NaB बनाम: DSS-induced IBD mice; 5-ASA control Outcome: IBD symptom alleviation and ferroptosis inhibition प्रभाव: None None

जनसंख्या: DSS-induced IBD murine model

In Vitro
Effects of Lactobacillus paracei JY062 Postbiotic on Intestinal Barrier, Immunity, and Gut Microbiota.
Dose: 5 mg/mL बनाम: LPS-treated cell models Outcome: Intestinal barrier function and gut microbiota प्रभाव: None None

जनसंख्या: Caco-2 cells, RAW264.7 macrophages, fecal fermentation

Other
Association of Inflammatory Factors and Calcium Metabolism With Arthritis in Patients With Inflammatory Bowel Disease: …
Dose: None बनाम: None Outcome: Causal associations IBD → arthritis subtypes (MR) प्रभाव: OR=1.21 (IBD→AS); OR=1.18 (IBD→PsA) <0.001 (AS); 0.007 (PsA)

जनसंख्या: Mendelian randomization study of IBD and arthritis

Observational Study n=212
Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology.
Dose: None बनाम: Healthy controls Outcome: CD-specific microbiome signatures (AUC 0.94) प्रभाव: AUC 0.94 in external validation None

जनसंख्या: Crohn's disease and ulcerative colitis patients

In Vitro
Effects of senotherapeutics on gut microbiome dysbiosis and intestinal inflammation in Crohn's disease: A pilot …
Dose: None बनाम: Untreated Crohn's disease microbiota Outcome: Gut microbiome modulation and inflammation प्रभाव: None None

जनसंख्या: Crohn's disease fecal microbiota in SHIME model

Key Statistics

2

अध्ययन

200

प्रतिभागी

Positive

C

ग्रेड

Referenced Papers

Langenbeck's archives of … 2025 3 उद्धरण
Digestion 2023 71 उद्धरण
Journal of Crohn's … 2022 23 उद्धरण
Terapevticheskii arkhiv 2019 50 उद्धरण
Current opinion in … 2019 5 उद्धरण
Current pharmaceutical design 2018 108 उद्धरण
PLoS computational biology 2018 29 उद्धरण
Gastroenterology 2017 335 उद्धरण
Best practice & … 2017 14 उद्धरण
Innate immunity 2017 13 उद्धरण
Inflammatory bowel diseases 2015 222 उद्धरण
Alimentary pharmacology & … 2005 227 उद्धरण
Alimentary pharmacology & … 2003 179 उद्धरण
Current opinion in … 2001 45 उद्धरण
Current opinion in … 2001 38 उद्धरण
Current opinion in … 2000 21 उद्धरण
Diseases of the … 1998 26 उद्धरण
The Journal of … 1994 29 उद्धरण
Digestive diseases (Basel, … 1993 29 उद्धरण

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

सामान्य रूप से उपयोग की जाने वाली खुराकें

general:
150-600 mg/day sodium or calcium butyrate
ibdsupport:
300-600 mg three times daily (900-1,800 mg/day)
butyrateenema:
100 mM butyrate enema for distal UC (clinical setting only)

अधिकतम सीमा: No established upper limit for oral supplements; most studies use 600-4,000 mg/day

अनुसंधान में अध्ययन की गई खुराकें

खुराक अवधि प्रभाव N
None -- Positive 140
Low-dose and high-dose NaB -- Positive --
5 mg/mL -- Positive --
None -- Positive --
None -- Positive 212
None -- Positive --
None -- Negative --
None -- Mixed --

सेवन का सर्वोत्तम समय: With meals; enteric-coated formulations recommended to reach the colon

Safety & Side Effects

रिपोर्ट किए गए दुष्प्रभाव

  • Unpleasant taste/odor (butyric acid has a strong rancid butter smell)
  • Mild GI discomfort (nausea, bloating)
  • Belching with butyric acid odor
  • Enteric-coated formulations reduce taste issues

ज्ञात अंतःक्रियाएँ

  • 5-ASA medications (mesalamine) — additive anti-inflammatory effect (potentially beneficial in IBD)
  • No significant adverse drug interactions known

सहनीय अधिकतम सेवन: No established upper limit for oral supplements; most studies use 600-4,000 mg/day

कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।

Frequently Asked Questions

Does Butyrate (Sodium/Calcium Butyrate) help with Crohn's Disease?
Based on 2 studies with 200 participants, there is limited but promising evidence that Butyrate (Sodium/Calcium Butyrate) may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much Butyrate (Sodium/Calcium Butyrate) should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 150-600 mg/day sodium or calcium butyrate. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Butyrate (Sodium/Calcium Butyrate)?
Reported side effects may include Unpleasant taste/odor (butyric acid has a strong rancid butter smell), Mild GI discomfort (nausea, bloating), Belching with butyric acid odor, Enteric-coated formulations reduce taste issues. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Butyrate (Sodium/Calcium Butyrate) and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.

Related Evidence

इसके लिए अन्य सामग्री Crohn's Disease

Butyrate (Sodium/Calcium Butyrate) अन्य स्वास्थ्य स्थितियों के लिए

FDA अस्वीकरण: इन कथनों का Food and Drug Administration द्वारा मूल्यांकन नहीं किया गया है। इस वेबसाइट पर उत्पादों और जानकारी का उद्देश्य किसी बीमारी का निदान, उपचार, इलाज या रोकथाम नहीं है। प्रस्तुत साक्ष्य ग्रेड प्रकाशित पीयर-रिव्यूड अनुसंधान के हमारे विश्लेषण पर आधारित हैं और चिकित्सा सलाह नहीं हैं। कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।